More recently, venetoclax was shown to enhance the effector activity of antileukemic T cells by increasing reactive oxygen species generation through inhibition of respiratory chain supercomplex formation, with azacitidine priming AML cells for killing by T cells by inducing a viral mimicry response through activation of the STING/cGAS pathway [41]. This evidence concerns the gene STING1 and acute myeloid leukemia.